Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, Meijer GA, van Krieken JH, Kuiper R, Punt CJ, Nagtegaal ID. Mekenkamp LJ, et al. Among authors: koopman m. BMC Cancer. 2012 Jul 17;12:292. doi: 10.1186/1471-2407-12-292. BMC Cancer. 2012. PMID: 22804917 Free PMC article.
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ. Koopman M, et al. Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1. Lancet. 2007. PMID: 17630036 Clinical Trial.
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Tol J, et al. Among authors: koopman m. N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. N Engl J Med. 2009. PMID: 19196673 Free article. Clinical Trial.
The CAIRO and FOCUS studies: which lesson is to be learned?
Koopman M, Seymour MT, Punt CJ. Koopman M, et al. Oncologist. 2009 Feb;14(2):192-3; author reply 194-6. doi: 10.1634/theoncologist.2008-0247. Oncologist. 2009. PMID: 19251907 Free article. No abstract available.
484 results